{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:19:47Z","timestamp":1792189187498,"version":"4.4.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":688,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Intensive Care"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1186\/s13613-024-01309-y","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T10:02:13Z","timestamp":1716372133000},"page":"80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Pneumocystis pneumonia in French intensive care units in 2013\u20132019: mortality and immunocompromised conditions"],"prefix":"10.1016","volume":"14","author":[{"given":"Toufik","family":"Kamel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Boulain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1186\/s13613-024-01309-y_bb0010","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s00436-015-4678-6","article-title":"Pneumocystis jirovecii\u2014from a commensal to pathogen: clinical and diagnostic review","volume":"114","author":"Sokulska","year":"2015","journal-title":"Parasitol Res"},{"issue":"4\u20135","key":"10.1186\/s13613-024-01309-y_bb0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1651-2227.1950.tb08530.x","article-title":"On interstitial plasma cell pneumonia in infants","volume":"39","author":"Gormsen","year":"1950","journal-title":"Acta Paediatr (Stockh)"},{"issue":"6","key":"10.1186\/s13613-024-01309-y_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1651-2227.1950.tb08550.x","article-title":"Interstitial plasma cell pneumonia; report of 2 cases","volume":"39","author":"Walther","year":"1950","journal-title":"Acta Paediatr (Stockh)"},{"issue":"44","key":"10.1186\/s13613-024-01309-y_bb0025","first-page":"1260","article-title":"Parasitic pneumonia caused by Pneumocystis carinii in a 60-year-old woman","volume":"91","author":"Vanek","year":"1952","journal-title":"Cas Lek Cesk"},{"issue":"3","key":"10.1186\/s13613-024-01309-y_bb0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/BF01704594","article-title":"Pneumocystis carinii pneumonia after 40 years","volume":"20","author":"Nouza","year":"1992","journal-title":"Infection"},{"issue":"10","key":"10.1186\/s13613-024-01309-y_bb0035","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3201\/eid1010.030985","article-title":"Current epidemiology of Pneumocystis pneumonia","volume":"10","author":"Morris","year":"2004","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1186\/s13613-024-01309-y_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.1988.03720080019021","article-title":"Safety and efficacy of sulfamethoxazole and trimethoprim chemoprophylaxis for Pneumocystis carinii pneumonia in AIDS","volume":"259","author":"Fischl","year":"1988","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1186\/s13613-024-01309-y_bb0045","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1086\/313843","article-title":"Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy","volume":"30","author":"Kaplan","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1186\/s13613-024-01309-y_bb0050","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3390\/ijerph19052768","article-title":"Trends in the epidemiology and outcomes of pneumocystis pneumonia among human immunodeficiency virus (HIV) hospitalizations","volume":"19","author":"Elango","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"24","key":"10.1186\/s13613-024-01309-y_bb0055","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1001\/jama.2009.880","article-title":"Evolving health effects of Pneumocystis: one hundred years of progress in diagnosis and treatment","volume":"301","author":"Kovacs","year":"2009","journal-title":"JAMA"},{"key":"10.1186\/s13613-024-01309-y_bb0060","doi-asserted-by":"crossref","unstructured":"Antiretroviral Therapy Cohort Collaboration (ART-CC), Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, Sabin C, Fatkenheuer G, Justice A, Reiss P, d'Arminio Monforte A, Gill J, Hogg R, Bonnet F, Kitahata M, Staszewski S, Casabona J, Harris R, Saag M. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS- defining conditions are created equal. Clin Infect Dis. 2009;48(8):1138\u201351. https:\/\/doi.org\/10.1086\/597468.","DOI":"10.1086\/597468"},{"issue":"3","key":"10.1186\/s13613-024-01309-y_bb0065","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3201\/eid1903.121151","article-title":"Increasing Pneumocystis pneumonia, England, UK, 2000\u20132010","volume":"19","author":"Maini","year":"2013","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1186\/s13613-024-01309-y_bb0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1099\/jmm.0.000617","article-title":"Changing epidemiology of Pneumocystis pneumonia, Northern Ireland, UK and implications for prevention, 1 July 2011-31 July 2012","volume":"66","author":"Patterson","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1186\/s13613-024-01309-y_bb0075","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s12281-019-00349-3","article-title":"Pneumocystis jirovecii pneumonia: epidemiology, clinical manifestation and diagnosis","volume":"13","author":"White","year":"2019","journal-title":"Curr Fungal Infect Rep"},{"issue":"4","key":"10.1186\/s13613-024-01309-y_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3390\/jof3040057","article-title":"Global and multi-national prevalence of fungal diseases-estimate precision","volume":"3","author":"Bongomin","year":"2017","journal-title":"J Fungi (Basel)"},{"issue":"9","key":"10.1186\/s13613-024-01309-y_bb0085","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1093\/cid\/ciy723","article-title":"Prevalence and etiology of community-acquired pneumonia in immunocompromised patients","volume":"68","author":"GLIMP Investigators","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1186\/s13613-024-01309-y_bb0090","doi-asserted-by":"crossref","first-page":"542.e1","DOI":"10.1016\/j.cmi.2022.12.014","article-title":"Aetiology, clinical features, diagnostic studies, and outcomes of community-acquired pneumonia in kidney transplant recipients admitted to hospital: a multicentre retrospective French cohort study","volume":"29","author":"Schwartz","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1186\/s13613-024-01309-y_bb0095","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.semarthrit.2018.10.018","article-title":"Pneumocystis jirovecii pneumonia (PJP) prophylaxis patterns among patients with rheumatic diseases receiving high-risk immunosuppressant drugs","volume":"48","author":"Schmajuk","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"7","key":"10.1186\/s13613-024-01309-y_bb0100","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41409-018-0391-2","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in allogeneic hematopoietic cell transplant recipients: can we always follow the guidelines?","volume":"54","author":"Redjoul","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1186\/s13613-024-01309-y_bb0105","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","article-title":"A new Simplifed Acute Physiology Score (SAPS II) based on a European\/North American multicenter study","volume":"270","author":"Le Gall","year":"1993","journal-title":"JAMA"},{"issue":"4","key":"10.1186\/s13613-024-01309-y_bb0110","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.mlr.0000118861.56848.ee","article-title":"Comparison of the Elixhauser and Charlson\/Deyo methods of comorbidity measurement in administrative data","volume":"42","author":"Southern","year":"2004","journal-title":"Med Care"},{"issue":"10","key":"10.1186\/s13613-024-01309-y_bb0115","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"RECORD Working Committee","year":"2015","journal-title":"PLoS Med"},{"issue":"11","key":"10.1186\/s13613-024-01309-y_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0113677","article-title":"Augmented backward elimination: a pragmatic and purposeful way to develop statistical models","volume":"9","author":"Dunkler","year":"2014","journal-title":"PLoS ONE"},{"issue":"3","key":"10.1186\/s13613-024-01309-y_bb0125","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection\u2014a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom J"},{"key":"10.1186\/s13613-024-01309-y_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2023.02.014","article-title":"Rising incidence of Pneumocystis pneumonia: a population-level descriptive ecological study in England","author":"Pates","year":"2023","journal-title":"J Infect"},{"issue":"18","key":"10.1186\/s13613-024-01309-y_bb0135","article-title":"Evolving epidemiology of pneumocystis pneumonia: Findings from a longitudinal population-based study and a retrospective multi-center study in Germany","volume":"15","author":"Kolbrink","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1186\/s13613-024-01309-y_bb0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3389\/fpubh.2019.00275","article-title":"Changing trends in the epidemiology and risk factors of pneumocystis pneumonia in Spain","volume":"7","author":"Pereira-Diaz","year":"2019","journal-title":"Front Public Health"},{"key":"10.1186\/s13613-024-01309-y_bb0145","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1186\/s12879-021-06144-1","article-title":"Epidemiological and clinical characteristics of immunocompromised patients infected with Pneumocystis jirovecii in a twelve-year retrospective study from Norway","volume":"21","author":"Gr\u00f8nseth","year":"2021","journal-title":"BMC Infect Dis"},{"issue":"7","key":"10.1186\/s13613-024-01309-y_bb0150","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10096-002-0758-5","article-title":"Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients","volume":"21","author":"Roblot","year":"2002","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"9","key":"10.1186\/s13613-024-01309-y_bb0155","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.3201\/eid2009.131668","article-title":"Pneumocystis jirovecii pneumonia in patients with or without AIDS","volume":"20","author":"Roux","year":"2014","journal-title":"France Emerg Infect Dis"},{"issue":"1","key":"10.1186\/s13613-024-01309-y_bb0160","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/cc6806","article-title":"Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection (Erratum in: Crit Care. 2009;13(2)407)","volume":"12","author":"Monnet","year":"2008","journal-title":"Crit Care"},{"issue":"2","key":"10.1186\/s13613-024-01309-y_bb0165","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1378\/chest.128.2.573","article-title":"Acute respiratory failure due to pneumocystis pneumonia in patients without human immunodeficiency virus infection: outcome and associated features","volume":"128","author":"Festic","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1186\/s13613-024-01309-y_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1465-9921-14-87","article-title":"Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia","volume":"14","author":"Lemiale","year":"2013","journal-title":"Respir Res"},{"issue":"10","key":"10.1186\/s13613-024-01309-y_bb0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/14787210.2019.1671823","article-title":"Pneumocystis pneumonia in the twenty-first century: HIV-infected versus HIV-uninfected patients","volume":"17","author":"Cill\u00f3niz","year":"2019","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1186\/s13613-024-01309-y_bb0180","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2016.03.018","article-title":"Pneumocystis pneumonia suspected cases in 604 non-HIV and HIV patients","volume":"46","author":"Bienvenu","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"12","key":"10.1186\/s13613-024-01309-y_bb0185","doi-asserted-by":"crossref","first-page":"1242.e11","DOI":"10.1016\/j.amjmed.2014.07.010","article-title":"Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients","volume":"127","author":"Fillatre","year":"2014","journal-title":"Am J Med"},{"issue":"12","key":"10.1186\/s13613-024-01309-y_bb0190","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.medcli.2019.01.010","article-title":"Pneumocystis jirovecii pneumonia prophylaxis in immunocompromised patients with systemic autoimmune diseases","volume":"152","author":"Braga","year":"2019","journal-title":"Med Clin (Barc)"},{"issue":"9","key":"10.1186\/s13613-024-01309-y_bb0195","doi-asserted-by":"crossref","first-page":"ofz315","DOI":"10.1093\/ofid\/ofz315","article-title":"Practice patterns of pneumocystis pneumonia prophylaxis in connective tissue diseases: a survey of infectious disease physicians","volume":"6","author":"Wolfe","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-024-01309-y_bb0200","doi-asserted-by":"crossref","unstructured":"R\u00faa-Figueroa Fern\u00e1ndez de Larrinoa \u00cd, Carreira PE, Brito Garc\u00eda N, D\u00edaz Del Campo Fontecha P, Pego Reigosa JM, G\u00f3mez Puerta JA, Ortega-Castro R, Tejera Segura B, Aguado Garc\u00eda JM, Torre-Cisneros J, Valencia-Mart\u00edn JL, Pereda CA, Nishishinya-Aquino MB, Ot\u00f3n S\u00e1nchez MT, Silva Fern\u00e1ndez L, Maese Manzano J, Chamizo Carmona E, Correyero Plaza M. Recommendations for prevention of infection in systemic autoimmune rheumatic diseases. Reumatol Clin (Engl Ed). 2022;18(6):317\u2013330. https:\/\/doi.org\/10.1016\/j.reumae.2021.04.003.","DOI":"10.1016\/j.reumae.2021.04.003"},{"issue":"8","key":"10.1186\/s13613-024-01309-y_bb0205","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s00296-021-04808-4","article-title":"Is cotrimoxazole prophylaxis against Pneumocystis jirovecii pneumonia needed in patients with systemic autoimmune rheumatic diseases requiring immunosuppressive therapies?","volume":"41","author":"Pereda","year":"2021","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1186\/s13613-024-01309-y_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00277-020-04297-8","volume":"100","author":"Christopeit","year":"2021","journal-title":"Ann Hematol"},{"issue":"12b","key":"10.1186\/s13613-024-01309-y_bb0215","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/imj.12599","article-title":"Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014","volume":"44","author":"Cooley","year":"2014","journal-title":"Intern Med J"},{"key":"10.1186\/s13613-024-01309-y_bb0220","article-title":"Pneumocystis jiroveci in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"AST Infectious Diseases Community of Practice","year":"2019","journal-title":"Clin Transplant"},{"issue":"6","key":"10.1186\/s13613-024-01309-y_bb0225","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1007\/s00277-021-04452-9","volume":"100","author":"Classen","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1186\/s13613-024-01309-y_bb0230","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jtct.2021.01.024","article-title":"Guidelines for infection prophylaxis, monitoring and therapy in cord blood transplantation","volume":"27","author":"American Society for Transplantation and Cellular Therapy Cord Blood Special Interest Group","year":"2021","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"10.1186\/s13613-024-01309-y_bb0235","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"12S","key":"10.1186\/s13613-024-01309-y_bb0240","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.bulcan.2021.11.001","volume":"108","author":"Paul","year":"2021","journal-title":"Bull Cancer"},{"issue":"83","key":"10.1186\/s13613-024-01309-y_bb0245","article-title":"French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis\u20142021 update. Full-length version","volume":"4","author":"Cottin","year":"2022","journal-title":"Respir Med Res"},{"key":"10.1186\/s13613-024-01309-y_bb0250","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-2334-9-47","article-title":"Serum markers in interstitial pneumonia with and without Pneumocystis jirovecii colonization: a prospective study","volume":"22","author":"Shimizu","year":"2009","journal-title":"BMC Infect Dis"},{"issue":"2","key":"10.1186\/s13613-024-01309-y_bb0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0246296","article-title":"Clinical characteristics and prognosis of patients with Pneumocystis jirovecii pneumonia without a compromised illness","volume":"16","author":"Kim","year":"2021","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1186\/s13613-024-01309-y_bb0260","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.3390\/diagnostics12122925","article-title":"Prognostic analysis of Pneumocystis Jirovecii pneumonia in interstitial lung disease patients: a retrospective clinical study","volume":"12","author":"Sun","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"10.1186\/s13613-024-01309-y_bb0265","doi-asserted-by":"crossref","first-page":"00306","DOI":"10.1183\/23120541.00306-2019","article-title":"Prognostic impact of pre-existing interstitial lung disease in non-HIV patients with Pneumocystis pneumonia","volume":"6","author":"Hamada","year":"2020","journal-title":"ERJ Open Res"},{"key":"10.1186\/s13613-024-01309-y_bb0270","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0140-6736(96)91468-3","article-title":"Pneumocystis carinii infection in patients with chronic bronchial disease","volume":"347","author":"Calder\u00f3n","year":"1996","journal-title":"Lancet"},{"key":"10.1186\/s13613-024-01309-y_bb0275","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijid.2022.12.027","article-title":"Pneumocystis jirovecii pneumonia in patients with decompensated cirrhosis: a case series","volume":"128","author":"Franceschini","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"11","key":"10.1186\/s13613-024-01309-y_bb0280","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/01.mlr.0000228018.48783.34","article-title":"Quality of diagnosis and procedure coding in ICD-10 administrative data","volume":"44","author":"Henderson","year":"2006","journal-title":"Med Care"},{"key":"10.1186\/s13613-024-01309-y_bb0285","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/ofid\/ofac109","article-title":"Pneumocystis jirovecii Pneumonia and Toxoplasmosis in PWH with HIV-controlled disease treated for solid malignancies: a DAT'AIDS study","volume":"9","author":"Pansu","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1186\/s13613-024-01309-y_bb0290","doi-asserted-by":"crossref","unstructured":"Giacobbe DR, et al; JIR-ICU investigators (collaborators); Critically Ill Patients Study Group of the European Society of Clinical Microbiology and Infectious Diseases (ESGCIP), and the Fungal Infection Study Group of the European Society of Clinical Microbiology and Infectious Diseases (EFISG). Pneumocystis Jirovecii pneumonia in intensive care units: a multicenter study by ESGCIP and EFISG. Crit Care. 2023;27:323. https:\/\/doi.org\/10.1186\/s13054-023-04608-1.","DOI":"10.1186\/s13054-023-04608-1"}],"container-title":["Annals of Intensive Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13613-024-01309-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025002274?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2110582025002274?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13613-024-01309-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:56:13Z","timestamp":1776671773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2110582025002274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"alternative-id":["S2110582025002274"],"URL":"https:\/\/doi.org\/10.1186\/s13613-024-01309-y","relation":{},"ISSN":["2110-5820"],"issn-type":[{"value":"2110-5820","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pneumocystis pneumonia in French intensive care units in 2013\u20132019: mortality and immunocompromised conditions","name":"articletitle","label":"Article Title"},{"value":"Annals of Intensive Care","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1186\/s13613-024-01309-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 The Author(s) 2024. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}],"article-number":"80"}}